An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment

Leslie R Rowe; Arthur R Brothman; William E Nibley; Michael R Gaffney; Zhong Chen

doi:10.1016/j.cancergencyto.2006.11.005

An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment

Cancer Genet Cytogenet. 2007 Apr 1;174(1):54-6. doi: 10.1016/j.cancergencyto.2006.11.005.

Authors

Leslie R Rowe¹, Arthur R Brothman, William E Nibley, Michael R Gaffney, Zhong Chen

Affiliation

¹ Institute for Clinical and Experimental Pathology, Associated Regional and University Pathologists (ARUP) Laboratories, 500 Chipeta Way, Salt Lake City, UT 84108-1221, USA. rowelr@aruplab.com

PMID: 17350467
DOI: 10.1016/j.cancergencyto.2006.11.005

Abstract

Secondary chromosomal changes are known to develop in Philadelphia chromosome-negative (Ph-) cells of chronic myelogenous leukemia (CML) patients after treatment with imatinib mesylate, an ABL kinase inhibitor. We report here a novel case of a pericentric inversion of chromosome 16 as the sole cytogenetic abnormality in Ph- cells after treatment of Ph+ CML with imatinib.

Publication types

Case Reports

MeSH terms

Aged
Benzamides
Chromosome Inversion / genetics*
Chromosomes, Human, Pair 16 / genetics*
Core Binding Factor beta Subunit / metabolism
Female
Humans
Imatinib Mesylate
Karyotyping
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Philadelphia Chromosome*
Piperazines / therapeutic use*
Pyrimidines / therapeutic use*

Substances

Benzamides
CBFB protein, human
Core Binding Factor beta Subunit
Piperazines
Pyrimidines
Imatinib Mesylate